Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS) is a healthcare company (drug manufacturers - specialty & generic) based in the United States. The share price is $16.80, up 0.60% on the day, which values the company at $3.07B. Price as of 18 Nov 2026, 12:25 UTC, from Yahoo Finance.
Key facts
- Share price
- $16.80+0.60% today
- Market value
- $3.07B
- Forward P/E
- 63.0×
- Funk Score
- 62/100
- 200-week average
- $4.57268% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Xeris Biopharma Holdings, Inc. in more detail
XERS trades at 63.0× next year's expected earnings, 8.3× sales. It sits 268% above its 200-week average of $4.57.
Over the last five fiscal years Xeris Biopharma Holdings, Inc. has compounded revenue 70.7% a year. Its Funk Score is 62 out of 100 (financial strength 3.9, profitability 4.7, growth 10.0, each out of 10).
In its favour: Altman Z in the safe zone; Strong Piotroski score. Worth checking: Share count keeps rising; Thin interest cover.
Xeris Biopharma Holdings, Inc. (XERS): questions and answers
What is Xeris Biopharma Holdings, Inc.'s market cap?
Xeris Biopharma Holdings, Inc. is valued at $3.07B at a share price of $16.80.
Is XERS above its 200-week moving average?
Yes. XERS is 267.7% above its 200-week average of $4.57. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Xeris Biopharma Holdings, Inc. growing?
Over the last five fiscal years Xeris Biopharma Holdings, Inc.'s revenue grew 70.7% a year.
Does XERS pay a dividend?
Xeris Biopharma Holdings, Inc. does not currently pay a regular dividend.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Xeris Biopharma Holdings, Inc. (XERS) stock: price, valuation and fundamentals”, data as of 18 November 2026. https://funkfolio.com/stock/XERS
Underlying data: Yahoo Finance; company filings with the SEC.